Trial: Catheter device cuts contrast use

A catheter-based device designed to reduce contrast media use was found to cut dose by more than 15% in interventional cardiac procedures, according to trial results presented on Wednesday at the Society for Cardiovascular Angiography and Interventions (SCAI) scientific sessions.

Contrast-induced nephropathy can cause rapid deterioration in kidney function, so doctors are careful to limit contrast media dose as much as possible in at-risk patients during interventional cardiac procedures.

At SCAI 2016, researchers from the Zena and Michael A. Wiener Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai presented their research on the Avert system from Osprey Medical. Avert uses proprietary technology designed to limit manual injection reflux, thereby reducing the amount of contrast that the patient's kidneys are exposed to. Once the desired amount of contrast has been administered, the contrast drains into a reservoir rather than into the patient's aorta.

The group performed a prospective, randomized, multicenter trial that enrolled 578 patients considered to be at risk of contrast-induced acute kidney injury. All were undergoing invasive coronary angiography with or without percutaneous coronary intervention (PCI). In all, 292 patients in the treatment group received hydration and used Avert. A control group of 286 patients received hydration only.

Among 568 patients with contrast-induced acute kidney injury, 239 (42.2%) received PCI. Avert produced a 15.5% relative reduction in contrast volume in all patients, and there was a 22.8% relative reduction in contrast volume for PCI patients. There were no significant differences in contrast-induced acute kidney injury or adverse event rates between the two groups.

The Avert system is safe and easy to use, and it reduces contrast volume without sacrificing image quality, said lead author Dr. Roxana Mehran, director of interventional cardiovascular research and clinical trials at the cardiovascular institute.

The study team received a grant from Osprey Medical.

Page 1 of 373
Next Page